Neuralink, Elon Musk's brain-computer interface company, received "breakthrough device" clearance from the FDA for its Blindsight technology, which aims to restore limited vision to blind individuals by embedding a microelectrode array in the visual cortex. While Musk claims it could enable even those blind from birth to see, experts caution that the technology is still in its early stages and faces significant challenges, such as the low density of electrodes, which currently produce only rudimentary visual phenomena. Despite these hurdles, Neuralink's advancements in electrode density and implantation methods are promising steps toward future electronic implant-based treatments for blindness. However, Musk's bold claims are premature, and more open discussion and research are needed to fully understand the device's potential.